Cost assessment of pharmacotherapy applied to patients affected by COVID-19 under invasive mechanical ventilation in a general hospital
Objective: To evaluate the profile of patients affected by COVID-19 who required invasive mechanical ventilation in relation to the prescription of anesthetics, neuromuscular blockers, sedatives, antimicrobials and anti-inflammatory drugs in a general hospital in Rio de Janeiro. The impact of the pandemic on the consumption and price variation of these drugs was also evaluated. Methods: A retrospective study in the form of a case series in which the inclusion criteria were: patients admitted to the intensive care unit between May and July 2020 with a diagnosis of COVID-19, with positive PCR laboratory test, submitted to invasive mechanical ventilation. Exclusion criteria were: patients under 18 years old. The drugs of interest were defined through a review of the literature produced in 2020, the analyzes were carried out in 5 phases: data collection carried out by the research pharmacists in prescriptions and in the consumption reports of the system used in the institution; identification of unit prices of drugs of interest; calculation of the overall cost of drug therapy for patients; calculation of cost in relation to drugs of interest; comparison of data referring to the interest group with data on complete therapy and identification of medications with greater financial prominence; identification of price variation in public purchases of medicines with the greatest financial prominence. Results: Eighteen patients were selected with a total cost of pharmacological treatment of U$ 49,602.24, with an average of U$ 2,755.68 ± U$ 2,425.31 per patient. The consumption of different therapeutic classes was observed, the most consumed items were enoxaparin, norepinephrine, meropenem, midazolam and rocuronium. These 6 drugs accounted for 43.3% of the total cost of pharmacotherapy and it can be seen that their prices increased by up to 1664.7%. Conclusions: The high consumption with the valuation of the observed items directly implied the high cost of therapy for these selected patients and the increased risk of drug shortages for the treatment, with reflections on the quality of care provided and on patient safety.
How to Cite
Copyright (c) 2021 Authors
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The authors hereby transfer, assign, or otherwise convey to RBFHSS: (1) the right to grant permission to republish or reprint the stated material, in whole or in part, without a fee; (2) the right to print republish copies for free distribution or sale; and (3) the right to republish the stated material in any format (electronic or printed). In addition, the undersigned affirms that the article described above has not previously been published, in whole or part, is not subject to copyright or other rights except by the author(s), and has not been submitted for publication elsewhere, except as communicated in writing to RHFHSS with this document.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC-BY-NC-ND) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
This journal permits and encourages authors to post and archive the final pdf of the articles submitted to the journal on personal websites or institutional repositories after publication, while providing bibliographic details that credit its publication in this journal.